<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17581" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Angiosarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Spiker</surname>
            <given-names>Alison M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mangla</surname>
            <given-names>Ankit</given-names>
          </name>
          <aff>Case Western Reserve University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramsey</surname>
            <given-names>Michael L.</given-names>
          </name>
          <aff>Geisinger Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alison Spiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ankit Mangla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Ramsey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17581.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Angiosarcoma is a tumor of endothelial cell-origin that comprises 1% of all soft tissue sarcomas. It is an aggressive malignancy that carries a poor prognosis, if not detected and treated in early stages. This activity describes the evaluation, diagnosis, and management of angiosarcoma and highlights the role of team-based interprofessional care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etioloigy, epidemiology, pathophysiology and pathology of angiosarcoma.</p></list-item><list-item><p>Review the presentation of angiosarcoma including patient history, physical exam and imaging findings.</p></list-item><list-item><p>Review the treatment options available for management of angiosarcoma</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team can enhance patient care when managing a patient with angiosarcoma to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17581&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17581">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17581.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Angiosarcoma (AS) comprises 1% of all soft-tissue sarcoma (STS), which are themselves a rare malignancy. They arise from lymphatic or vascular endothelial cells and are 'high-grade' by definition, which demonstrates their aggressive behavior.<xref ref-type="bibr" rid="article-17581.r1">[1]</xref>&#x000a0;Although AS can occur in any part of the body, it most commonly presents as a cutaneous disease in elderly white men or on the chest wall after receiving radiation therapy (RT) for breast cancer.<xref ref-type="bibr" rid="article-17581.r2">[2]</xref>&#x000a0;The treatment is very challenging, and the prognosis is poor, especially if AS is diagnosed in the metastatic stage. The best approach to patients with AS is offered in a multidisciplinary tumor board setting. Like any other STS, surgical resection with a negative margin affords the best outcomes in terms of overall survival.&#x000a0;<xref ref-type="bibr" rid="article-17581.r3">[3]</xref><xref ref-type="bibr" rid="article-17581.r4">[4]</xref>&#x000a0;Combining radiation therapy (RT) with weekly paclitaxel has been demonstrated to bear durable responses for cutaneous angiosarcoma.<xref ref-type="bibr" rid="article-17581.r4">[4]</xref>&#x000a0;Doxorubicin and paclitaxel are recommended regimens for advanced or metastatic disease.<xref ref-type="bibr" rid="article-17581.r5">[5]</xref> Due to the increased vascularity of AS, targeted therapy against vascular endothelial growth factor (VEGF) has gained traction, however, yet remains to be proven in a prospective study.<xref ref-type="bibr" rid="article-17581.r2">[2]</xref></p>
      </sec>
      <sec id="article-17581.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>AS is mostly a spontaneous tumor; however, a transformation from a benign vascular lesion has been reported previously. Radiation-induced AS is commonly seen in breast cancer survivors who receive RT to the chest wall. However, it can occur in any part of the body that has been irradiated previously. Stewart-Treves syndrome is defined as AS occurring in the setting of chronic lymphedema. Chronic lymphedema can occur with cancer and its treatment, infection like filariasis (Milroy's disease).</p>
        <p>A few case reports suggest an association of AS with mutation in the DNA repair genes BRCA1 and BRCA2. Familial syndromes like neurofibromatosis, Maffuci syndrome, Klippel-Trenaunay syndrome are also associated with AS. chemicals like vinyl chloride, thorium dioxide, arsenic, radium, anabolic steroids are also associated with AS.<xref ref-type="bibr" rid="article-17581.r1">[1]</xref></p>
      </sec>
      <sec id="article-17581.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Overall STS comprises 1% of all malignancies. AS comprises up to 2% of all STS and 5-4% of all cutaneous STS.<xref ref-type="bibr" rid="article-17581.r6">[6]</xref><xref ref-type="bibr" rid="article-17581.r7">[7]</xref>&#x000a0;AS has a similar distribution between sexes; however, is more common in elderly white men.<xref ref-type="bibr" rid="article-17581.r7">[7]</xref> It can develop in any body organ, but cutaneous AS occurs more commonly in the head and neck region, particularly in the scalp.<xref ref-type="bibr" rid="article-17581.r7">[7]</xref> Being a more of endothelial origin, AS can also occur rarely in major blood vessels and the heart.<xref ref-type="bibr" rid="article-17581.r5">[5]</xref><xref ref-type="bibr" rid="article-17581.r1">[1]</xref></p>
      </sec>
      <sec id="article-17581.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologic diagnosis of AS is challenging. Morphologic differences are very subtle and it is hard to distinguish between a benign proliferation of vessels versus AS. AS is infiltration and is devoid of a capsule, hence it is hard to distinguish normal from abnormal tissue. Abnormal, pleomorphic, malignant endothelial cells&#x000a0;are the hallmark of&#x000a0;AS. These cells&#x000a0;can be rounded,&#x000a0;polygonal, or fusiform and can have an epithelioid appearance.<xref ref-type="bibr" rid="article-17581.r1">[1]</xref></p>
        <p>In the well-differentiated areas, abnormal endothelial cells form functioning vascular sinusoid continuous with normal vascular channels. As the aggressiveness of the tumor increases, the architecture gets more distorted and the abnormal cells stack in multiple layers and form papillary like projections into the vascular lumen. In poorly differentiated areas, the malignant epithelial cells form an epithelioid morphology with areas of hemorrhage and necrosis, which make it difficult to distinguish from anaplastic carcinoma or melanoma.<xref ref-type="bibr" rid="article-17581.r1">[1]</xref></p>
        <p>Immunohistochemistry plays a critical role in identifying AS. As typically express endothelial markers&#x000a0;including von Willebrand factor, CD34, CD31, Ulex europaeus agglutinin 1, and VEGF. Von Willebrand&#x000a0;factor, U europaeus agglutinin 1, and CD31 are the most&#x000a0;useful markers in poorly differentiated cases. It is imperative to check for melanocytic markers (S-100, human melanoma black-45, and melanoma antigen) to rule out melanoma.<xref ref-type="bibr" rid="article-17581.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17581.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical exam are mandatory for any patient presenting with a mass suspicious for malignancy. History of receiving RT to a body part, especially if it was received a decade ago, should raise the suspicion for STS, including AS. Family history of AS is extremely rare, but must be covered in each patient. A history of exposure to chemicals (listed above) must be obtained. A history of surgical removal of lymph nodes, chronic lymphedema, and parasitic infections can provide a clue towards diagnosis.&#x000a0;</p>
        <p>Physical exam should evaluate for lymphedema, nail changes, or hair changes (a sign of exposure to harmful chemicals), radiation burns, previous scars from surgery and RT. Cutaneous AS can resemble a bruise or a raised purple-red papule. As the tumor size increases, it becomes ulcerated, fungating, bleeds easily, and is associated with tissue infiltration. Typically it is a multifocal disease.<xref ref-type="bibr" rid="article-17581.r9">[9]</xref>&#x000a0;Visceral AS usually presents with a mass effect where the enlarging tumor compresses the nearby structure and causes obstructive symptoms. They spread via hematogenous route, with lung, bone, and other soft-tissue structures.<xref ref-type="bibr" rid="article-17581.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17581.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Laboratory studies are usually&#x000a0;unremarkable&#x000a0;unless mass effect causes compression of critical organs and causes laboratory abnormalities (E.g., compression of the ureter can lead to renal failure), or the disease is fairly advanced to cause subtle lab abnormalities (anemia of chronic disease, elevated sedimentation rate, etc.). However, no lab abnormality can specifically point towards&#x000a0;a diagnosis of AS.&#x000a0;</p>
        <p>Advanced imaging like CT scan, MRI, or PET scan is required to define the anatomy of the tumor and the extent of spread.<xref ref-type="bibr" rid="article-17581.r11">[11]</xref> In the case of special locations, like the heart, a 3-dimensional echocardiogram may also be needed.<xref ref-type="bibr" rid="article-17581.r5">[5]</xref>&#x000a0;Angiosarcoma is one of the few sarcomas that can metastasize widely in the body, including the brain and the lymph nodes. Hence, the initial staging workup includes an MRI of the brain with and without contrast, a CT scan of the chest, and a CT scan of the abdomen and pelvis. Also, unlike most other STS where CT chest (with or without contrast) is usually sufficient for surveillance, patients with angiosarcoma must be followed with a CT scan of the chest, abdomen, and pelvis. The administration of iodine-based contrast is dependent on the patient profile.</p>
        <p>The final diagnosis is established via biopsy and histopathology.&#x000a0;</p>
      </sec>
      <sec id="article-17581.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Any patient diagnosed with STS benefits from a multidisciplinary approach. The same applies to AS. The treatment for AS can be divided based on the stage of presentation (metastatic versus non-metastatic).</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-metastatic disease:
<list list-type="bullet"><list-item><p>Local surgery with R0 resection is the treatment of choice.<xref ref-type="bibr" rid="article-17581.r2">[2]</xref>&#x000a0;R1 and R2 resection confer a worse prognosis.<xref ref-type="bibr" rid="article-17581.r9">[9]</xref><xref ref-type="bibr" rid="article-17581.r12">[12]</xref><xref ref-type="bibr" rid="article-17581.r9">[9]</xref> Due to the infiltrative nature of AS, wide margins are advised.</p></list-item><list-item><p>AS is a high-grade malignancy. Hence peri-operative RT is always recommended. Small retrospective studies have demonstrated a survival benefit with local control.<xref ref-type="bibr" rid="article-17581.r9">[9]</xref></p></list-item><list-item><p>No study has shown a clear benefit to adjuvant chemotherapy. However, neoadjuvant chemotherapy can be considered in patients where the tumor size is large, and achieving negative margins may be challenging.<xref ref-type="bibr" rid="article-17581.r1">[1]</xref></p></list-item><list-item><p>In patients with locally advanced cutaneous-AS, small retrospective studies have shown benefit of adding weekly paclitaxel to RT to improve local control rates and prolong survival.<xref ref-type="bibr" rid="article-17581.r4">[4]</xref></p></list-item><list-item><p>Localized visceral angiosarcoma is a disease associated with high morbidity and mortality. A multimodality approach combining surgery, radiotherapy, and chemotherapy must be used. Recent reports have demonstrated the benefit and safety of using proton beam therapy combined with chemotherapy for cardiac angiosarcoma.<xref ref-type="bibr" rid="article-17581.r13">[13]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Metastatic disease: Metastatic disease is treated with chemotherapy. Cytotoxic agents, targeted therapy, and Immune checkpoint inhibitors are being explored in treating metastatic disease.&#x000a0;
<list list-type="bullet"><list-item><p>Cytotoxic chemotherapy- anthracycline-based regimens are usually the first line of treatment in a patient with any STS. However, in patients with AS, paclitaxel is an effective drug with comparable response rates to anthracyclines.
<list list-type="bullet"><list-item><p>Anthracyclines- In patients with STS, the response rate is between 16-36%. In most cases, a combination with another drug, ifosfamide, certainly increases toxicity but may not benefit the outcome.<xref ref-type="bibr" rid="article-17581.r14">[14]</xref>&#x000a0;Liposomal doxorubicin has also shown therapeutic responses in patients with AS.<xref ref-type="bibr" rid="article-17581.r15">[15]</xref></p></list-item><list-item><p>Taxanes: The antiangiogenic properties of taxanes make them useful in patients with AS. After numerous retrospective studies reporting benefits in AS, a small phase II prospective study (ANGIOTAX study) showed an ORR of 17%. However, two of the five patients with responses underwent surgery and achieved a complete pathological response.<xref ref-type="bibr" rid="article-17581.r16">[16]</xref>&#x000a0;Since then, multiple studies have confirmed the activity of weekly paclitaxel in patients with AS.<xref ref-type="bibr" rid="article-17581.r17">[17]</xref>&#x000a0;Paclitaxel is administered as 80mg/m2 on days 1, 8, 15 of a 28-day cycle.</p></list-item><list-item><p>Other cytotoxic drugs like Ifosfamdie, Gemcitabine, Cisplatin are also active in patients with AS; however, they are usually not used as the first line of treatment.</p></list-item></list>
</p></list-item><list-item><p>Targeted therapy
<list list-type="bullet"><list-item><p>Anti-VEGF molecule- Since AS is a malignancy arising from vascular endothelium, anti-VEGF therapy, particularly bevacizumab, gained a lot of attention for metastatic AS. However, a prospective phase II study failed to show any benefit.<xref ref-type="bibr" rid="article-17581.r2">[2]</xref></p></list-item><list-item><p>Tyrosine Kinase inhibitors (TKI)- Several TKI (Sorafenib, Pazopanib, Axitinib, and regorafenib) have been tested in patients with AS. The drugs mainly target either VEGF or PDGFRA, which are critical to the growth of AS. Unfortunately, none of these drugs showed a beneficial response, despite clinical activity in patients with AS.</p></list-item></list>
</p></list-item><list-item><p>Immune checkpoint inhibitors (ICI).&#x000a0;
<list list-type="bullet"><list-item><p>Recent data suggest that ICI may be active in patients with AS.<xref ref-type="bibr" rid="article-17581.r18">[18]</xref>&#x000a0;This is yet to be tested in a prospective trial.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17581.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>AS is one of the over 70 different subtypes of STS.<xref ref-type="bibr" rid="article-17581.r3">[3]</xref>&#x000a0;It is also included in the broad category of the vascular tumors that make the bulk of differential diagnosis for AS.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Reactive and benign vascular tumors
<list list-type="bullet"><list-item><p>Capillary haemangiomas</p></list-item><list-item><p>Juvenile haemangioma (strawberry naevus)</p></list-item><list-item><p>Cherry angioma (Campbell de Morgan spot)</p></list-item><list-item><p>Pyogenic granuloma</p></list-item><list-item><p>Cavernous haemangiomas</p></list-item><list-item><p>Epithelioid haemangioma</p></list-item><list-item><p>Vascular ectasis (naevus flammus, spider naevus)</p></list-item><list-item><p>Angiomatosis</p></list-item><list-item><p>Postradiation atypical vascular lesion</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Intermediate grade vascular tumors
<list list-type="bullet"><list-item><p>Kaposi&#x02019;s sarcoma</p></list-item><list-item><p>Epithelioid haemangioendothelioma</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Malignant vascular tumors
<list list-type="bullet"><list-item><p>Angiosarcoma</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Tumors of perivascular cells
<list list-type="bullet"><list-item><p>Haemangiopericytoma (solitary fibrous tumor)</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17581.s10" sec-type="Staging">
        <title>Staging</title>
        <p>The staging of AS is done like any other STS.<xref ref-type="bibr" rid="article-17581.r3">[3]</xref> By definition, AS is a high-grade tumor that confirms its aggressive nature.</p>
      </sec>
      <sec id="article-17581.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>AS has a 5-year survival of nearly 35%.<xref ref-type="bibr" rid="article-17581.r12">[12]</xref> Even with localized disease amenable to resection with negative margins, only 60% of patients are alive at 5 years (median survival of 7 months).<xref ref-type="bibr" rid="article-17581.r19">[19]</xref>&#x000a0;Old age, metastatic disease at presentation, and poor performance status have been consistently shown to be predictors of poor outcome. In addition to this, AS of atypical locations like liver and heart, and RT induced AS also have a very poor prognosis.<xref ref-type="bibr" rid="article-17581.r3">[3]</xref><xref ref-type="bibr" rid="article-17581.r20">[20]</xref>&#x000a0;Tumor size of more than 5 cm has been associated with a worse outcome in some studies.<xref ref-type="bibr" rid="article-17581.r1">[1]</xref></p>
      </sec>
      <sec id="article-17581.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The patients and physicians must understand the rarity and the aggressive nature of the disease, and the need for multidisciplinary discussions. Although no large randomized trials have been done specifically for AS, retrospective data clearly shows the survival benefit of local control which involves surgery with perioperative RT. Despite of good local control measures, recurrence rates are high, and a close follow up with frequent imaging is mandatory.</p>
      </sec>
      <sec id="article-17581.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Angiosarcoma is rare cancer and hence the data is scarce to drive evidence-based decision making. Despite that, certain approaches have shown clear benefits.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>History of RT, chronic lymphedema, and exposure to chemicals like vinyl chloride have been linked with the development of AS.</p>
          </list-item>
          <list-item>
            <p>Multidisciplinary tumor board discussion is a must for any patient diagnosed with angiosarcoma.</p>
          </list-item>
          <list-item>
            <p>R0 resection with perioperative RT is the best approach for local control of the disease.</p>
          </list-item>
          <list-item>
            <p>A combination of paclitaxel with RT has been demonstrated to achieve durable responses in patients with cutaneous AS.</p>
          </list-item>
          <list-item>
            <p>Weekly paclitaxel as a first-line treatment for AS has comparative efficacy to anthracycline-based regimens in patients with AS.</p>
          </list-item>
          <list-item>
            <p>Targeted therapy with anti-VEGF and anti-PDGFRA drugs has not to be proven to be beneficial over conventional chemotherapy, although did add to the toxicity of the regimen.</p>
          </list-item>
          <list-item>
            <p>Immune checkpoint inhibitors are currently being explored as a potential option for the treatment of AS.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17581.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The rarity of angiosarcoma has prevented clinicians from conducting large randomized clinical trials. This is the precise reason for discussing all patients with AS in a multidisciplinary tumor board to offer them the best approach. An expert pathologist trained in sarcoma specialty must be present at these tumor boards to appropriately identify AS and differentiate it from other tumor types, especially melanoma. Since local control offers the best survival outcome, surgical oncologists must collaborate with radiation oncologists to offer surgery with perioperative RT. Medical oncologists can offer concurrent chemotherapy and RT to the patients to achieve durable responses. Treating physicians must collaborate with radiologists to determine the results of the follow-up imaging and to discuss the best imaging modality in order to appropriately diagnose a patient with AS. Lastly, nurses, chemotherapy suites, and social workers must come together to provide comprehensive care to the patient. [Level III to Level IV]</p>
        <p>Due to the rarity of the pathology, no large randomized trials are possible, and the evidence of treatment comes from case series, retrospective studies of international registries, and few small prospective trials. [Level III to Level IV]</p>
      </sec>
      <sec id="article-17581.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17581&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17581">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/angiosarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17581">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17581/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17581">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17581.s16">
        <title>References</title>
        <ref id="article-17581.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Woll</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Angiosarcoma.</article-title>
            <source>Lancet Oncol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>983</fpage>
            <page-range>983-91</page-range>
            <pub-id pub-id-type="pmid">20537949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Woll</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Anti-angiogenic therapies for the treatment of angiosarcoma: a&#x000a0;clinical update.</article-title>
            <source>Memo</source>
            <year>2017</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>190</fpage>
            <page-range>190-193</page-range>
            <pub-id pub-id-type="pmid">29250195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Menon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mangla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <chapter-title>Leiomyosarcoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">31869131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujisawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okiyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor.</article-title>
            <source>Front Oncol</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">29552543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mangla</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Primary pericardial angiosarcoma: case report and review of treatment options.</article-title>
            <source>Ecancermedicalscience</source>
            <year>2020</year>
            <volume>14</volume>
            <fpage>1056</fpage>
            <pub-id pub-id-type="pmid">32582371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guillou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Le Doussal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Collin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ranch&#x000e8;re</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sastre</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Vilain</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Bonichon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>N'Guyen Bui</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group.</article-title>
            <source>Cancer</source>
            <year>2001</year>
            <month>May</month>
            <day>15</day>
            <volume>91</volume>
            <issue>10</issue>
            <fpage>1914</fpage>
            <page-range>1914-26</page-range>
            <pub-id pub-id-type="pmid">11346874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rouhani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Toro</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>113</volume>
            <issue>3</issue>
            <fpage>616</fpage>
            <page-range>616-27</page-range>
            <pub-id pub-id-type="pmid">18618615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohsawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawamori</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kanno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases.</article-title>
            <source>Cancer</source>
            <year>1995</year>
            <month>Jun</month>
            <day>15</day>
            <volume>75</volume>
            <issue>12</issue>
            <fpage>2867</fpage>
            <page-range>2867-74</page-range>
            <pub-id pub-id-type="pmid">7773935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pawlik</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Paulino</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>McGinn</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sondak</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.</article-title>
            <source>Cancer</source>
            <year>2003</year>
            <month>Oct</month>
            <day>15</day>
            <volume>98</volume>
            <issue>8</issue>
            <fpage>1716</fpage>
            <page-range>1716-26</page-range>
            <pub-id pub-id-type="pmid">14534889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hillenbrand</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Menge</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hohenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Primary and secondary angiosarcomas: a comparative single-center analysis.</article-title>
            <source>Clin Sarcoma Res</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">26413264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tokmak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ozkan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ya&#x0011f;c&#x00131;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>K&#x00131;r</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>F18-FDG PET/CT Scanning in Angiosarcoma: Report of Two Cases.</article-title>
            <source>Mol Imaging Radionucl Ther</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>63</fpage>
            <page-range>63-6</page-range>
            <pub-id pub-id-type="pmid">23486298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fayette</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Piperno-Neumann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Cesne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonvalot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ranch&#x000e8;re</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pouillart</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases.</article-title>
            <source>Ann Oncol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>2030</fpage>
            <page-range>2030-6</page-range>
            <pub-id pub-id-type="pmid">17974557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mangla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mansur</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Abboud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rothermel</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Right atrial cardiac angiosarcoma treated with concurrent proton beam therapy and paclitaxel: A novel approach to a rare disease.</article-title>
            <source>Thorac Cancer</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>1131</fpage>
            <page-range>1131-1133</page-range>
            <pub-id pub-id-type="pmid">33605065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mocellin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nitti</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-27</page-range>
            <pub-id pub-id-type="pmid">16338075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skubitz</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.</article-title>
            <source>Cancer</source>
            <year>2005</year>
            <month>Jul</month>
            <day>15</day>
            <volume>104</volume>
            <issue>2</issue>
            <fpage>361</fpage>
            <page-range>361-6</page-range>
            <pub-id pub-id-type="pmid">15948172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Bay</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Cupissol</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ray-Coquard</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Piperno-Neumann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kerbrat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taieb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isambert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peyrade</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chevreau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bompas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brain</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Nov</month>
            <day>10</day>
            <volume>26</volume>
            <issue>32</issue>
            <fpage>5269</fpage>
            <page-range>5269-74</page-range>
            <pub-id pub-id-type="pmid">18809609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apice</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pizzolorusso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Maio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gebbia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Buonadonna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Chiara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fazioli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Palma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galizia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arcara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mozzillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma.</article-title>
            <source>Sarcoma</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>6862090</fpage>
            <pub-id pub-id-type="pmid">27019606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Florou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Wieder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Komanduri</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Kolonias</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Uduman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Buell</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Trent</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wilky</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.</article-title>
            <source>J Immunother Cancer</source>
            <year>2019</year>
            <month>Aug</month>
            <day>08</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>213</fpage>
            <pub-id pub-id-type="pmid">31395100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hornicek</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Harmon</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Springfield</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Raskin</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mankin</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kirsch</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Desphpande</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Suit</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>DeLaney</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Treatment and outcome of 82 patients with angiosarcoma.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>1953</fpage>
            <page-range>1953-67</page-range>
            <pub-id pub-id-type="pmid">17356953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17581.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eitan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Damico</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Pidikiti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kharouta</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Dobbins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jesseph</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mangla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teknos</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Mansur</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Machtay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Reirradiation for Recurrent Scalp Angiosarcoma: Dosimetric Advantage of PBT over VMAT and EBT.</article-title>
            <source>Int J Part Ther</source>
            <year>2020</year>
            <season>Winter</season>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>13</fpage>
            <page-range>13-18</page-range>
            <pub-id pub-id-type="pmid">32582810</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
